Jurgen Grunberg
Villigen, AG 5232, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 10 publications
Phosphoproteomics Reveals L1CAM-Associated Signaling Networks in High-Grade Serous Ovarian Carcinoma: Implications for Radioresistance and Tumorigenesis.
Journal: International journal of molecular sciences
Published: March 21, 2025
161Tb-Based Anti-L1CAM Radioimmunotherapy Shows Superior Efficacy in Eliminating Ovarian Cancer Stem Cells Compared with 177Lu in Preclinical Models of Ovarian Cancer.
Journal: Journal of nuclear medicine : official publication, Society of Nuclear Medicine
Published: November 04, 2024
Targeting virulence regulation to disarm Acinetobacter baumannii pathogenesis.
Journal: Virulence
Published: October 20, 2022
Novel Therapeutic Strategies for Ovarian Cancer Stem Cells.
Journal: Frontiers in oncology
Published: September 30, 2019
Combination of lutetium-177 labelled anti-L1CAM antibody chCE7 with the clinically relevant protein kinase inhibitor MK1775: a novel combination against human ovarian carcinoma.
Journal: BMC cancer
Published: February 07, 2018
Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
Journal: European journal of nuclear medicine and molecular imaging
Published: February 28, 2014
Future prospects for SPECT imaging using the radiolanthanide terbium-155 - production and preclinical evaluation in tumor-bearing mice.
Journal: Nuclear medicine and biology
Published: September 29, 2013
DOTA-functionalized polylysine: a high number of DOTA chelates positively influences the biodistribution of enzymatic conjugated anti-tumor antibody chCE7agl.
Journal: PloS one
Published: December 20, 2012
Showing 1-10 of 10
Last Updated: 09/26/2026